Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 56
BPC-157 in Q3 2026: the FDA panel vote
The FDA's compounding panel voted 8 to 6 in July 2026 to back BPC-157 for the 503A bulks list, overruling its own reviewers. The evidence did not move.
GLP-1 and GIP: a short incretin history
Incretins went from a failed 1906 diabetes experiment to GLP-1 and GIP drugs. Here are the dates, the discoveries, and where the evidence thins out.
GLP-1 safety in neuroendocrine tumours
A 2026 European Journal of Endocrinology review weighs the evidence on GLP-1 receptor agonists like semaglutide in neuroendocrine neoplasms.
Grey Market Semaglutide: Injection Errors
A 20-person study found untrained adults completed only 15 of 34 steps correctly when preparing grey market semaglutide from internet instructions.
MASLD and cardiovascular risk explained
MASLD affects 38% of adults worldwide and heart disease kills more of them than liver failure. Where semaglutide fits, and what remains unproven.
Semaglutide and the septic rat heart
A 2026 rat study reports semaglutide limited sepsis-related heart injury by suppressing ferroptosis. There is no human data behind it.
Tirzepatide and a rash: one case report
A 2026 JAAD case report links a year of tirzepatide to a widespread rash that cleared when the drug stopped. One patient is not a risk rate.
Tirzepatide: 17% weight loss in real care
A 107-patient Spanish cohort reports 17.21% mean weight loss on tirzepatide at six months, at a median 7.5 mg dose. There is no control arm.
Why weight loss stalls on tirzepatide
A weight loss plateau is the expected shape of the tirzepatide curve, not a failure. Here is what the trials show and where retatrutide really stands.
BPC-157, gentamicin and the rat kidney
A 2026 Zagreb rat study says BPC-157 blunted gentamicin kidney damage. Here is what a rodent nephrotoxicity result can and cannot tell a human reader.
Does the eGFR dip explain heart benefit?
A 376-patient Saudi cohort asked whether the early eGFR change explains heart outcomes on dapagliflozin plus semaglutide. The answer was no.
GLP-1 timing and pregnancy blood pressure
A 2026 meta-analysis of three cohorts found no significant link between GLP-1 use around conception and hypertensive disorders of pregnancy.